Literature DB >> 19299522

Development of a high-throughput brain slice method for studying drug distribution in the central nervous system.

Markus Fridén1, Frederic Ducrozet, Brian Middleton, Madeleine Antonsson, Ulf Bredberg, Margareta Hammarlund-Udenaes.   

Abstract

New, more efficient methods of estimating unbound drug concentrations in the central nervous system (CNS) combine the amount of drug in whole brain tissue samples measured by conventional methods with in vitro estimates of the unbound brain volume of distribution (V(u,brain)). Although the brain slice method is the most reliable in vitro method for measuring V(u,brain), it has not previously been adapted for the needs of drug discovery research. The aim of this study was to increase the throughput and optimize the experimental conditions of this method. Equilibrium of drug between the buffer and the brain slice within the 4 to 5 h of incubation is a fundamental requirement. However, it is difficult to meet this requirement for many of the extensively binding, lipophilic compounds in drug discovery programs. In this study, the dimensions of the incubation vessel and mode of stirring influenced the equilibration time, as did the amount of brain tissue per unit of buffer volume. The use of cassette experiments for investigating V(u,brain) in a linear drug concentration range increased the throughput of the method. The V(u,brain) for the model compounds ranged from 4 to 3000 ml . g brain(-1), and the sources of variability are discussed. The optimized setup of the brain slice method allows precise, robust estimation of V(u,brain) for drugs with diverse properties, including highly lipophilic compounds. This is a critical step forward for the implementation of relevant measurements of CNS exposure in the drug discovery setting.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19299522     DOI: 10.1124/dmd.108.026377

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  34 in total

Review 1.  Reliability of In Vitro and In Vivo Methods for Predicting the Effect of P-Glycoprotein on the Delivery of Antidepressants to the Brain.

Authors:  Yi Zheng; Xijing Chen; Leslie Z Benet
Journal:  Clin Pharmacokinet       Date:  2016-02       Impact factor: 6.447

2.  In-depth neuropharmacokinetic analysis of antipsychotics based on a novel approach to estimate unbound target-site concentration in CNS regions: link to spatial receptor occupancy.

Authors:  I Loryan; E Melander; M Svensson; M Payan; F König; B Jansson; M Hammarlund-Udenaes
Journal:  Mol Psychiatry       Date:  2016-01-26       Impact factor: 15.992

Review 3.  Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approach.

Authors:  Kathryn Ball; François Bouzom; Jean-Michel Scherrmann; Bernard Walther; Xavier Declèves
Journal:  AAPS J       Date:  2013-06-20       Impact factor: 4.009

Review 4.  Methodologies to assess drug permeation through the blood-brain barrier for pharmaceutical research.

Authors:  Céline Passeleu-Le Bourdonnec; Pierre-Alain Carrupt; Jean Michel Scherrmann; Sophie Martel
Journal:  Pharm Res       Date:  2013-06-26       Impact factor: 4.200

5.  Improved measurement of drug exposure in the brain using drug-specific correction for residual blood.

Authors:  Markus Fridén; Helena Ljungqvist; Brian Middleton; Ulf Bredberg; Margareta Hammarlund-Udenaes
Journal:  J Cereb Blood Flow Metab       Date:  2009-09-16       Impact factor: 6.200

6.  Mechanistic understanding of brain drug disposition to optimize the selection of potential neurotherapeutics in drug discovery.

Authors:  Irena Loryan; Vikash Sinha; Claire Mackie; Achiel Van Peer; Wilhelmus Drinkenburg; An Vermeulen; Denise Morrison; Mario Monshouwer; Donald Heald; Margareta Hammarlund-Udenaes
Journal:  Pharm Res       Date:  2014-03-13       Impact factor: 4.200

7.  Population PKPD modeling of BACE1 inhibitor-induced reduction in Aβ levels in vivo and correlation to in vitro potency in primary cortical neurons from mouse and guinea pig.

Authors:  Juliette Janson; Susanna Eketjäll; Karin Tunblad; Fredrik Jeppsson; Stefan Von Berg; Camilla Niva; Ann-Cathrin Radesäter; Johanna Fälting; Sandra A G Visser
Journal:  Pharm Res       Date:  2013-10-03       Impact factor: 4.200

8.  Brain exposure of the ATM inhibitor AZD1390 in humans-a positron emission tomography study.

Authors:  Aurelija Jucaite; Per Stenkrona; Zsolt Cselényi; Serena De Vita; Nuria Buil-Bruna; Katarina Varnäs; Alicia Savage; Andrea Varrone; Peter Johnström; Magnus Schou; Chris Davison; Andy Sykes; Venkatesh Pilla Reddy; Matthias Hoch; Ana Vazquez-Romero; Mohammad Mahdi Moein; Christer Halldin; Melinda S Merchant; Martin Pass; Lars Farde
Journal:  Neuro Oncol       Date:  2021-04-12       Impact factor: 12.300

9.  Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of Alzheimer disease.

Authors:  Fredrik Jeppsson; Susanna Eketjäll; Juliette Janson; Sofia Karlström; Susanne Gustavsson; Lise-Lotte Olsson; Ann-Cathrine Radesäter; Bart Ploeger; Gvido Cebers; Karin Kolmodin; Britt-Marie Swahn; Stefan von Berg; Tjerk Bueters; Johanna Fälting
Journal:  J Biol Chem       Date:  2012-10-09       Impact factor: 5.157

10.  Influence of lipophilicity on drug partitioning into sclera, choroid-retinal pigment epithelium, retina, trabecular meshwork, and optic nerve.

Authors:  Rajendra S Kadam; Uday B Kompella
Journal:  J Pharmacol Exp Ther       Date:  2009-11-19       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.